There isn't that much middle ground when it comes to Danish CNS specialty pharmaceutical company H Lundbeck A/S (OTCPK:HLUYY)
- sell-side analysts either think it is an overvalued company with
little chance of differentiating its new products in the market or they
think it is an undervalued company that can drive significant value
through advanced drug design methods that lead to products with better
efficacy and/or safety profiles. With the recent clinical failure of
desmoteplase and an unimpressive initial ramp for Brintellix and Abilify
Maintena the bears are looking stronger of late, but I believe this
risky specialty pharma company still has a few strong cards left to
play.
Continue reading here:
Lundbeck Remains A High-Risk/High-Reward Specialty Pharmaceutical Play
No comments:
Post a Comment